Heart:双侧与单个胸廓内动脉移植物5年费用的随机比较

2019-04-08 xiangting MedSci原创

5年随访时,BITA的指数成本仍然较高,这主要是由于较高的初始成本引起的,随后1到5年随访期间没有出现后续差异。

与使用单个胸内动脉(SITA)的冠脉旁路移植术(CABG)相比,使用双侧胸内动脉(BITA)进行CABG可以提高生存率。这项研究评估了BITA与SITA相比的长期成本。

2004年6月至2007年12月,来自7个国家28家医院的3102名患者被随机分配为使用BITA(n=1548)或SITA(n=1554)进行CABG手术。从最初的医院事件中收集详细的资源使用数据,并每年收集直至5年。从英国的角度评估资源使用的相关成本,计算每个试验组和预先选择患者亚组的5年总成本。

每个组的总费用每年增加约1000英镑,试验组间没有显著的年度差异。与SITA组相比(17480英镑;平均成本差异1149英镑,95%CI 330英镑到1968英镑,p=0.006),由于初始手术的成本较高,5年随访时BITA组每位患者的累积成本显著升高(18629英镑)。试验组间与医疗接触、用药或严重不良事件相关的成本没有显著差异。

5年随访时,BITA的指数成本仍然较高,这主要是由于较高的初始成本引起的,随后1到5年随访期间没有出现后续差异。在10年随访的主要终点评估2种手术的总成本效益将取决于成本复合差异和质量调整生存率。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745313, encodeId=854e1e453133b, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Dec 24 08:47:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357155, encodeId=e7e5135e155c4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522430, encodeId=8c941522430e9, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563078, encodeId=f9e515630e89c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620732, encodeId=bc271620e3248, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-12-24 xuyong535
  2. [GetPortalCommentsPageByObjectIdResponse(id=1745313, encodeId=854e1e453133b, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Dec 24 08:47:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357155, encodeId=e7e5135e155c4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522430, encodeId=8c941522430e9, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563078, encodeId=f9e515630e89c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620732, encodeId=bc271620e3248, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-04-10 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1745313, encodeId=854e1e453133b, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Dec 24 08:47:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357155, encodeId=e7e5135e155c4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522430, encodeId=8c941522430e9, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563078, encodeId=f9e515630e89c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620732, encodeId=bc271620e3248, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1745313, encodeId=854e1e453133b, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Dec 24 08:47:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357155, encodeId=e7e5135e155c4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522430, encodeId=8c941522430e9, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563078, encodeId=f9e515630e89c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620732, encodeId=bc271620e3248, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-04-10 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1745313, encodeId=854e1e453133b, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Dec 24 08:47:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357155, encodeId=e7e5135e155c4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522430, encodeId=8c941522430e9, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563078, encodeId=f9e515630e89c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620732, encodeId=bc271620e3248, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Wed Apr 10 00:47:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]

相关资讯

国内首例87岁CABG同期AVR术

讯 近日,在北京友谊医院心外科接受冠状动脉旁路移植术(CABG)同期心脏瓣膜置换术(AVR)的87岁郭老先生欣喜地向笔者讲述是北京友谊医院的专家们让他摆脱了多年疾病的困扰。乐观又风趣的老人说自己术后的感觉就像排除掉了身体里的定时炸弹一样,感到身心愉悦,快乐无比。他连连竖起大拇指夸赞他身边的医护人员并抱拳表示感谢。 多年疾患 病情危重 郭老先生5年前无明显诱因间断出现胸闷症状

JAMA:冠脉旁路移植术与PCI在血运重建方面各有所长

研究要点: 1.对于与糖尿病患者,冠脉旁路移植术(CABG)治疗效果要优于PCI。 2.无保护左主干病变,多支冠状动脉病变及存在左室功能不全的患者,需根据病变复杂度及手术可行性来选择治疗方式。 3.医疗工作者需要考虑疾病复杂性,患者合并症,患者嗜好及当地治疗水平来选择血运重建治疗方式。 缺血性心脏病是造成患者死亡的主要原因,冠状动脉旁路移植手术(

JAHA:术前他汀类药物对非体外循环冠脉旁路移植术后急性肾损伤的影响

术前使用他汀类药物和他汀类药物剂量均不增加患者OPCAB后的AKI风险。